GAGE2A (G antigen 2A) is a cancer-germline (CG) gene located on the X chromosome X encodes a tumor-associated antigen presented by HLA class I molecules and recognized by CD8+ cytolytic T lymphocytes 1. As an X-linked cancer-germline gene, GAGE2A is normally silent in somatic tissues but becomes aberrantly activated in various tumor types, making it a potential target for cancer immunotherapy 2. The gene's expression is regulated by DNA methylation, with 74% of CG genes classified as DNA methylation-dependent, including most X-linked CG genes like GAGE2A 2. Functionally, GAGE2A has been identified as a mediator of chemoresistance in small cell lung cancer, where it contributes to therapeutic resistance mechanisms 3. The gene shows variable expression patterns across different cancer types, being detected in hepatocellular carcinoma where it serves as a prognostic biomarker 4, prostate cancer 5, pediatric rhabdomyosarcoma 1, melanoma 6, and salivary gland tumors 7. Interestingly, GAGE2A exhibits transient maternal imprinting and contributes to transcriptional sexual dimorphism in early embryos 2. Its tumor-specific expression profile makes GAGE2A a promising candidate for targeted immunotherapy approaches in cancer treatment.